Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Open accessThe DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Abstract
Background: The glutamatergic modulator ketamine has created a blueprint for studying novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic psychedelics (SPs) may also have antidepressant efficacy. Both ketamine and SPs appear to produce rapid, sustained antidepressant effects after a transient psychoactive period. Methods: This review summarizes areas of overlap between SP and ketamine research and considers the possibility of a common, downstream mechanism of action. The therapeutic relevance of the psychoactive state, overlapping cellular and molecular effects, and overlapping electrophysiological and neuroimaging observations are all reviewed. Results: Taken together, the evidence suggests a potentially shared mechanism wherein both ketamine and SPs may engender rapid neuroplastic effects in a glutamatergic activity-dependent manner. It is postulated that, though distinct, both ketamine and SPs appear to produce acute alterations in cortical network activity that may initially produce psychoactive effects and later produce milder, sustained changes in network efficiency associated with therapeutic response. However, despite some commonalities between the psychoactive component of these pharmacologically distinct therapies—such as engagement of the downstream glutamatergic pathway—the connection between psychoactive impact and antidepressant efficacy remains unclear and requires more rigorous research. Conclusions: Rapid-acting antidepressants currently under investigation may share some downstream pharmacological effects, suggesting that their antidepressant effects may come about via related mechanisms. Given the prototypic nature of ketamine research and recent progress in this area, this platform could be used to investigate entirely new classes of antidepressants with rapid and robust actions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In recent years, accumulating evidence indicates that psychedelic compounds that bind 5-HT 2A Rs rapidly promote neural plasticity both structurally and functionally, suggesting that this is a potential mechanism underlying the therapeutic effects of psychedelics (Olson, 2018;Inserra et al., 2021a;Kadriu et al., 2021).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Kadriu et al., 2021
In the citing paper
“In recent years, accumulating evidence indicates that psychedelic compounds that bind 5-HT 2A Rs rapidly promote neural plasticity both structurally and functionally, suggesting that this is a potential mechanism underlying the therapeutic effects of psychedelics (Olson, 2018;Inserra et al., 2021a;Kadriu et al., 2021).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Kadriu et al., 2021
In the citing paper
“Ketamine and its enantiomers do not only antagonize the N-methyl-D-aspartate (NMDA) receptors, but also induce rapid brain-derived neurotrophic factor (BDNF) translation and release in brain areas, which is supposed to be responsible for neuroplastic effects [17].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [17]
In the citing paper
“To date, reviews have focused on establishing treatment efficacy [30], understanding the neurological mechanisms of change [71], or have been broad in their aims (e.g. including a variety of drug classes or disorders [72, 73];).”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [73]
In the citing paper
“Recent studies have shown that NMDA receptor antagonists like ketamine and 5-HT2A receptor agonists like serotonergic psychedelics (the most studied include lysergic acid diethylamide/LSD and psilocybin) induce rapid and sometimes robust antidepressant effects190-193.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [192]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Buzsáki, G. (2006) · doi:10.1093/acprof:oso/9780195301069.001.0001 · Cited by 4,873
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“This AMPA activity appears to be critical, as rodent studies found that AMPA antagonists abolished ketamine’s behavioral, antidepressant, and mTORstimulating effects (Moghaddam et al., 1997; Maeng et al., 2008; Li et al., 2010).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“ketamine injections resulted in an antidepressant response observed concurrently with increased brain-derived neutrotrophic factor (Bdnf) gene expression and translation in the hippocampus and across the cortex (Garcia et al., 2008; Autry et al., 2011; Silva Pereira et al., 2017).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Research works printed but not linked: 1
- McKenna, 2018, New world tryptamine hallucinogens and the neuroscience of ayahuasca., 283
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
“This has been hypothesized to be modulated by increases in BDNF/TrkB signaling [192].”
BackgroundKundakovic, M., & Rocks, D. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101010 · Cited by 317
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citationInflammatory signaling mechanisms in bipolar disorder
Jones, G. H., Vecera, C. M., Pinjari, O. F., & Machado‐Vieira, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00742-6 · Cited by 160
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Just recently, the glutamatergic modulator ketamine was discovered as a new treatment option for MDD, which exerts antidepressant effects in minutes to hours that persist long after drug excretion [17].”
BackgroundBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 118
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Kantrowitz, J. T., Dong, Z., Milak, M. S., Rashid, R., Kegeles, L. S., Javitt, D. C., Lieberman, J. A., & John Mann, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01541-1 · Cited by 100
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.710004 · Cited by 85
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“…evidence indicates that psychedelic compounds that bind 5-HT 2A Rs rapidly promote neural plasticity both structurally and functionally, suggesting that this is a potential mechanism underlying the therapeutic effects of psy-chedelics (Olson, 2018; Inserra et al., 2021a; Kadriu et al., 2021).”
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“Synth-eses of the evidence for psychedelics ’ antidepressant mechanisms of action propose that, like typical antidepressants and ketamine, psychedelics facilitate neuroplasticity at the behavioral, network, and synaptic levels [130, 131].”
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Self-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“The classical psychedelics may share glutamatergic activitydependent neuroplastic effects with ketamine (175) and on a longer timescale, with some types of conventional antidepressants (176).”
BackgroundMuscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.710338 · Cited by 63
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Psychedelic-Assisted Therapy for People with Eating Disorders
Gukasyan, N., Schreyer, C. C., Griffiths, R. R., & Guarda, Á. S. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01394-5 · Cited by 35
Wolfson, P., & Vaid, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1209419 · Cited by 34
A review of pre-clinical models for Gulf War Illness
Ribeiro, A. C. R., & Deshpande, L. S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107936 · Cited by 34
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
Szpręgiel, I., & Bysiek, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00660-y · Cited by 32
Sarasso, P., Billeci, M., Ronga, I., Raffone, F., Martiadis, V., & Petta, G. D. (2024) · Psychopathology · doi:10.1159/000539714 · Cited by 32
Serotonergic Psychedelics in Neural Plasticity
Lukasiewicz, K., Baker, J. J., Zuo, Y., & Lu, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.748359 · Cited by 31
Rapid-acting antidepressant drugs modulate affective bias in rats
Hinchcliffe, J. K., Stuart, S. A., Wood, C. M., Bartlett, J. M., Kamenish, K., Arban, R., Thomas, C. W., Selimbeyoglu, A., Hurley, S., Hengerer, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2403 · Cited by 31
Bonnelle, V., Smith, W., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P. C., Ramaekers, J. G., & Feilding, A. (2022) · British Journal of Pain · doi:10.1177/20494637221114962 · Cited by 30
Beating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 30
Averill, L. A., Jiang, L., Purohit, P., Coppoli, A., Averill, C. L., Roscoe, J., Kelmendi, B., Feyter, H. M. D., de Graaf, R. A., Gueorguieva, R. V., et al. (2022) · Chronic Stress · doi:10.1177/24705470221092734 · Cited by 27
Preclinical models of treatment-resistant depression: challenges and perspectives
Kolasa, M., & Faron‐Górecka, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00542-9 · Cited by 27
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“, 1998) and head-twitch responses in mice (GonzalezMaeso et al., 2007; Keiser et al., 2009).”
Psychedelic Psychotherapy: Building Wholeness Through Connection
Vaid, G., & Walker, B. (2022) · Global Advances in Health and Medicine · doi:10.1177/2164957x221081113 · Cited by 26
Dahan, J. D. C., Dadiomov, D., Bostoen, T., & Dahan, A. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00091-w · Cited by 24
Quintanilla, B., Zarate, C. A., & Pillai, A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02507-7 · Cited by 23
Self-citationThe Essentiality of Amino Acids in Healthiness and Disease State: Type II Diabetes as a Case Study
Fayomi, S. I., Erukainure, O. L., & Msomi, N. Z. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70346 · Cited by 22
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
“This allowed us to assess rapid antidepressant effects, which typically appear immediately after PAT (Kadriu et al., 2021).”
BackgroundZhang, Y., Wei, C., Wang, P., Zheng, L.-C., Cheng, Y., Ren, Z., Jin, Y., Yao, Y., & Liu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-76226-y · Cited by 20
Psychedelics and the treatment of eating disorders: considerations for future research and practice
Lacroix, E., Fatur, K., Hay, P., Touyz, S. W., & Keshen, A. R. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01125-6 · Cited by 16
Non-sedative cortical EEG signatures of allopregnanolone and functional comparators
Lambert, P. M., Ni, R., Benz, A. M., Rensing, N. R., Wong, M., Zorumski, C. F., & Mennerick, S. J. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01450-x · Cited by 16
Rossi, G. N., Hallak, J. E. C., Baker, G. B., Dursun, S. M., & SANTOS, R. G. D. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01460-2 · Cited by 16
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
Sarasso, P., Tschacher, W., Schoeller, F., Francesetti, G., Roubal, J., Gecele, M., Sacco, K., & Ronga, I. (2024) · Physics of Life Reviews · doi:10.1016/j.plrev.2024.09.005 · Cited by 13
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
Exploring the impact of music on response to ketamine/esketamine: A scoping review
Kheirkhah, M., Nugent, A. C., Livinski, A. A., Neely, L., Johnson, S. C., Henter, I. D., Varnosfaderani, S. D., Price, R. B., Hejazi, N. S., Yavi, M., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105693 · Cited by 13
Self-citationKojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Self-citationPalhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
Muscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2022) · Psych · doi:10.3390/psych4010012 · Cited by 13
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“including a variety of drug classes or disorders [72, 73];).”
BackgroundThe ketamine chameleon: history, pharmacology, and the contested value of experience
Diep, D., de la Salle, S., Lévesque, J. T., Lifshitz, M., Garel, N., & Greenway, K. T. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2459377 · Cited by 11
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021012 · Cited by 11
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025) · The Neuroscientist · doi:10.1177/10738584251403946 · Cited by 10
Maldegem, M. V., Vohryzek, J., Atasoy, S., Alnagger, N., Cardone, P., Bonhomme, V. L., Vanhaudenhuyse, A., Demertzi, A., Jaquet, O., Bahri, M. A., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.12.036 · Cited by 10
Mikellides, G. (2025) · Psychoactives · doi:10.3390/psychoactives4030020 · Cited by 9
Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies
Santos, G. H. D. M., Rodrigues, L. S., Rocha, J. M., Rossi, G. N., Oña, G., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2023) · Psychoactives · doi:10.3390/psychoactives2010006 · Cited by 9
Beaglehole, B., Porter, R., Douglas, K. M., Lacey, C. J., de Bie, A., Jordan, J., Mentzel, C., Thwaites, B., Manuel, J., Murray, G., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084844 · Cited by 9
Microbiota-derived psychedelics: Lessons from COVID-19
Sfera, A., Hazan, S., Kozlakidis, Z., & Klein, C. A. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/159477 · Cited by 8
Kupferberg, A., & Hasler, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1372650 · Cited by 7
Impact of psychedelics on craving in addiction: A systematic review
Chapron, S., Bonazzi, G., Lodovico, L. D., de Ternay, J., Landmann, C., Nourredine, M., Salvo, F., Sessa, B., Das, R., Rolland, B., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241308613 · Cited by 7
Glutamate modulators and beyond: A neuroscience revolution in the making
Zarate, C. A. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.09.005 · Cited by 7
Self-citationGold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
Is Use of Psychedelic Drugs a Risk or Protective Factor for Late-Life Cognitive Decline?
Fearn, K., & Bhattacharyya, K. K. (2024) · Gerontology and Geriatric Medicine · doi:10.1177/23337214241250108 · Cited by 5
Chruścicka‐Smaga, B., Machaczka, A., Szewczyk, B., & Pilc, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00547-4 · Cited by 5
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4
Wang, Z., Zhang, Y., & Li, X. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae059.134 · Cited by 4
Psilocybin-assisted psychotherapy in adults with depression – A literature review
Dorczok, M. C., Mittmann, G., Ettl, T., & Steiner‐Hofbauer, V. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111508 · Cited by 4
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Hilal, F. F., Jeanblanc, J., & Naassïla, M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023028 · Cited by 4
Boltaev, U., Park, H. W., Brown, K. R., Delgado, M., Wu, J., Diaz-Pacheco, B. N., Botero-Pinzon, M., He, K., Ahern, E., Goldshmid, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.04.583022 · Cited by 4
Targeting Neuroinflammation in Depression: The Integrative Role of Sigma‐1 Receptor Modulation
Wang, J., Yang, D., Li, Y., & Ren, P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70490 · Cited by 3
Modification of natural tryptamines for the treatment of neuropsychiatric diseases
Palfreyman, M. G., Varty, G. B., Stang, E. M., Boltaev, U., Avery, K., & Nivorozhkin, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368362 · Cited by 3
Formolo, D. A., Cheng, T., & Yau, S. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae059.135 · Cited by 3
Dynapenia is associated with a higher risk of depressive symptoms among older adults
Chang, C.-C., Liao, Y., Chen, J., Lai, T., Hsueh, M., Park, J., & Chang, Y.-J. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1533973 · Cited by 3
Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions
Iorgu, A.-M., Vasilescu, A.-N., Pfeiffer, N., Spanagel, R., Mallien, A. S., Inta, D., & Gass, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01699-3 · Cited by 3
Psychedelics, Atheism, and Naturalism Myth and Reality
Letheby, C. (2022) · Journal of Consciousness Studies · doi:10.53765/20512201.29.7.069 · Cited by 3
Petrovitch, D., Victor, S. E., Schmidt, A. T., Schmitz, J. M., Meyer, T. D., Stotts, A. L., & Littlefield, A. K. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00371-y · Cited by 3
Handschuh, P. A., Konadu, M. E., Spurny‐Dworak, B., Silberbauer, L., Murgaš, M., & Lanzenberger, R. R. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_18 · Cited by 2
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Chapter 20. Psychopharmacology
Mulsant, B. H., & Pollock, B. G. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds20 · Cited by 1
Ketamine, Dissociation, and Depression: What Is “Special” About Ketamine? (Revisited)
Rizk, M., & Murrough, J. W. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae024 · Cited by 1
Arjmand, S., Lindström, M., Sellgren, C. M., & Wegener, G. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2025.14 · Cited by 1
Virtual Reality: A New Tool for Anxiolysis, Distraction, and Analgesia
Mason, K. P., & Hoffman, H. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-68468-5_44 · Cited by 1
Courtes, A. C., Myers, B., Daly, N., Jones, G., Soares, J. C., Zarate, C. A., & Machado‐Vieira, R. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.011 · Cited by 1
Self-citationThe romantic age of pharmacological science
Witkin, J. M. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173354 · Cited by 1
Turkia, M. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9yxwp · Cited by 1
Turkia, M. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9yxwp_v2 · Cited by 1
Basedow, L. A., Lottes, L., Falkenberg, I., Vogelbacher, C., & Yildiz, C. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/6hjkm_v1 · Cited by 1
Dominant Narratives in Contemporary Psychedelic Medicine
Kennedy, M. (2024) · eScholarship@McGill (McGill) · doi:10.82308/35669 · Cited by 1
Translational research investigating psilocybin: underlying neurobiological mechanisms
van den Berg, M. M. J. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230120mb
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
Is anti-NMDA receptor encephalitis real? II. Therapeutic challenges
Snedkov, E. V., Анатольевич, В. И., & Lemeshev, I. V. (2024) · Neurology Bulletin · doi:10.17816/nb624112
Chapter 21. Ketamine and Esketamine
Mathai, D. S., & Mathew, S. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as21
Psychedelic Drugs as Treatment Agents
Yehuda, R., Lepow, L., Bonnano, P. A., Zaretsky, T. G., Antonio, J. H., & Jagodnik, K. M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0074
Staging, Functioning, and Cognition
Kupka, R., Scott, J. L., & Hillegers, M. H. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_10
Metadata
- Authors
- Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kadriu, Bashkim
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-30
- Volume
- 24
- Issue
- 1
- Pages
- 8-21
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816692
- OpenAlex
- W3108229983
- Cited by
- 99
- References
- 145
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 22 · 2023: 15 · 2022: 23 · 2021: 12 · 2020: 1
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health
- National Institutes of Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, serotonergic psychedelics, rapid-acting antidepressants, antidepressant mechanism, glutamatergic signaling, cortical network activity, psychoactive effects, network efficiency
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Hallucinogens, Humans, Ketamine, Serotonin Agents, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.